Carisma Therapeutics (CARM) Competitors $0.31 0.00 (-1.12%) Closing price 04:00 PM EasternExtended Trading$0.33 +0.02 (+6.17%) As of 05:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CARM vs. EVGN, INMB, IZTC, UNCY, VRCA, HOWL, IFRX, ICCC, ATHE, and DTILShould you be buying Carisma Therapeutics stock or one of its competitors? The main competitors of Carisma Therapeutics include Evogene (EVGN), INmune Bio (INMB), Invizyne Technologies (IZTC), Unicycive Therapeutics (UNCY), Verrica Pharmaceuticals (VRCA), Werewolf Therapeutics (HOWL), InflaRx (IFRX), ImmuCell (ICCC), Alterity Therapeutics (ATHE), and Precision BioSciences (DTIL). These companies are all part of the "medical" sector. Carisma Therapeutics vs. Its Competitors Evogene INmune Bio Invizyne Technologies Unicycive Therapeutics Verrica Pharmaceuticals Werewolf Therapeutics InflaRx ImmuCell Alterity Therapeutics Precision BioSciences Carisma Therapeutics (NASDAQ:CARM) and Evogene (NASDAQ:EVGN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, media sentiment, analyst recommendations and institutional ownership. Do analysts rate CARM or EVGN? Carisma Therapeutics presently has a consensus target price of $1.93, suggesting a potential upside of 525.00%. Evogene has a consensus target price of $3.50, suggesting a potential upside of 193.87%. Given Carisma Therapeutics' higher possible upside, research analysts clearly believe Carisma Therapeutics is more favorable than Evogene.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Carisma Therapeutics 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 2.71Evogene 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor CARM or EVGN? In the previous week, Carisma Therapeutics and Carisma Therapeutics both had 1 articles in the media. Carisma Therapeutics' average media sentiment score of 0.00 equaled Evogene'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Carisma Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Evogene 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals have more ownership in CARM or EVGN? 44.3% of Carisma Therapeutics shares are held by institutional investors. Comparatively, 10.4% of Evogene shares are held by institutional investors. 6.9% of Carisma Therapeutics shares are held by company insiders. Comparatively, 7.4% of Evogene shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has more volatility and risk, CARM or EVGN? Carisma Therapeutics has a beta of 1.79, suggesting that its stock price is 79% more volatile than the S&P 500. Comparatively, Evogene has a beta of 1.59, suggesting that its stock price is 59% more volatile than the S&P 500. Is CARM or EVGN more profitable? Evogene has a net margin of -224.82% compared to Carisma Therapeutics' net margin of -254.28%. Carisma Therapeutics' return on equity of 0.00% beat Evogene's return on equity.Company Net Margins Return on Equity Return on Assets Carisma Therapeutics-254.28% N/A -137.38% Evogene -224.82%-102.40%-39.19% Which has preferable earnings and valuation, CARM or EVGN? Evogene has lower revenue, but higher earnings than Carisma Therapeutics. Evogene is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCarisma Therapeutics$19.96M0.64-$60.48M-$1.56-0.20Evogene$8.51M0.75-$16.49M-$2.69-0.44 SummaryCarisma Therapeutics beats Evogene on 8 of the 15 factors compared between the two stocks. Get Carisma Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CARM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CARM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CARM vs. The Competition Export to ExcelMetricCarisma TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.87M$2.53B$5.57B$9.51BDividend YieldN/A1.80%4.74%4.13%P/E Ratio-0.209.2029.1824.41Price / Sales0.64601.03433.45171.81Price / CashN/A22.2824.4827.20Price / Book-0.465.008.525.77Net Income-$60.48M$31.61M$3.24B$264.99M7 Day Performance-15.69%-3.00%-0.79%-2.13%1 Month Performance-24.14%5.68%8.00%7.06%1 Year Performance-68.41%0.43%27.39%20.81% Carisma Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CARMCarisma Therapeutics2.3547 of 5 stars$0.31-1.1%$1.93+525.0%-68.1%$12.87M$19.96M-0.2020Upcoming EarningsGap DownEVGNEvogene2.0972 of 5 stars$1.28-2.3%$3.50+173.4%-76.0%$7.03M$8.51M-0.48140Positive NewsINMBINmune Bio2.426 of 5 stars$2.91+7.4%$18.40+532.3%-68.7%$63.92M$50K-1.5110News CoverageUpcoming EarningsAnalyst DowngradeGap UpIZTCInvizyne TechnologiesN/A$9.98+0.3%N/AN/A$62.40MN/A0.0029Positive NewsGap UpUNCYUnicycive Therapeutics2.4083 of 5 stars$4.71-3.3%$60.00+1,173.9%-3.1%$61.56M$680K-0.929Short Interest ↑VRCAVerrica Pharmaceuticals3.9945 of 5 stars$6.79+2.7%$80.00+1,078.2%-90.3%$61.14M$7.57M-0.5740Short Interest ↑HOWLWerewolf Therapeutics3.9044 of 5 stars$1.35-0.7%$8.33+517.3%-45.0%$61.03M$1.88M-0.8140IFRXInflaRx3.1911 of 5 stars$0.88-2.4%$6.60+652.7%-41.5%$60.33M$180K-1.0760Upcoming EarningsGap UpICCCImmuCell0.0658 of 5 stars$6.70+1.3%N/A+57.1%$59.74M$26.49M-95.6970Gap UpATHEAlterity Therapeutics1.7591 of 5 stars$5.58-14.8%$12.00+115.1%+257.9%$58.08MN/A0.0010Gap UpHigh Trading VolumeDTILPrecision BioSciences4.0902 of 5 stars$5.10-1.0%$47.00+821.6%-50.4%$57.10M$51.14M-2.54200Upcoming Earnings Related Companies and Tools Related Companies Evogene Alternatives INmune Bio Alternatives Invizyne Technologies Alternatives Unicycive Therapeutics Alternatives Verrica Pharmaceuticals Alternatives Werewolf Therapeutics Alternatives InflaRx Alternatives ImmuCell Alternatives Alterity Therapeutics Alternatives Precision BioSciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CARM) was last updated on 8/4/2025 by MarketBeat.com Staff From Our PartnersREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut with the old (A.I.) - In with the new (E.I.)One expert predicts that E.I. could see over 200,000% growth... But you need to move fast...Behind the Markets | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredStrange twist to Bitcoin’s rallyThe #1 crypto to buy today Better than Bitcoin? (top crypto for less than $1) Over the past 15 years, B...Stansberry Research | Sponsored[Warning] Buffett Indicator hits new All-Time-HighWarren Buffett has leaned on one key indicator for decades—and it just hit an all-time high. That’s not bullis...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Carisma Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Carisma Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CARM Stock Alerts